| You
are here: Home: BCU 4|2001: Section 4
Section 4
Randomized Trial of Docetaxel-Capecitabine
versus Docetaxel
FUTURE TRIALS
LOOKING AT DOCETAXEL-CAPECITABINE
One issue relates
to weekly docetaxel or paclitaxel with capecitabine, and it makes
a lot of sense because if you’re up-regulating the thymidine
phosphorylase with the taxane, you’d like to give that taxane
over a longer time period — not just once every three weeks.
And there are phase I studies very close to completion for both
docetaxel and paclitaxel with capecitabine. And phase II studies
will very soon be getting underway. Another question relates to
combining docetaxel and capecitabine with trastuzumab. And for the
patient with a HER2 overexpressing tumor, that’s another important
research question.
In the adjuvant
setting, we’d like to look at a comparison of AC versus docetaxel-capecitabine
in node-negative or ER/PR-positive, node-positive breast cancer.
Another research issue is that as the role of the taxanes is better
defined in the adjuvant setting — particularly in patients
with ER-negative tumors — the obvious thought is to add capecitabine
in with the taxane to see if you can save more lives. And I would
guess you probably could, if you can define the subset of women
who will benefit from taxanes in the adjuvant setting.
—Joyce
O’Shaughnessy, MD
-
Review Select Publications
-
Review Other Clinical Trials
Page
4of 4
Back
|
